Oncology Conference update

ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

Publication Date

Sep 2024

download

Scroll down to see the full video series and navigate through tabs to select your video update.

 

GI cancer highlights from ESMO 2024

 

GI cancer highlights from ESMO 2024

GI cancer highlights from ESMO 2024

Dr Lizzy Smyth and Dr Sam Klempner share their views on practice-changing upper GI cancer data presented at the ESMO 2024 congress.   

 

Watch and listen as the experts reveal what they consider to be the key takeaways and how the new data could impact clinical practice.

 

Clinical takeaways

  • AGITG TOPGEAR: Results showed that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients with resectable gastric and gastro-oesophageal junction cancer. The trial results confirm that neoadjuvant chemoradiotherapy has no role in the treatment of operable gastric and gastroesophageal junction adenocarcinoma [Leong T, et al. Abstract LBA58, ESMO 2024 ]
  • SPACE-FLOT: A retrospective dataset suggesting that pathological response to neoadjuvant FLOT predicts efficacy of adjuvant FLOT therapy. Interesting dataset, but randomised clinical trials required to confirm this finding [Lee M, et al. Abstract 1402MO, ESMO 2024]
  • KEYNOTE-811: First-line treatment with the immunotherapy combination, pembrolizumab added to trastuzumab and chemotherapy (5-FU or CAPOX), significantly improves overall survival in HER2-positive metastatic gastric/ gastroesophageal junction adenocarcinoma [Janjigian Y, et al. Abstract 1400O, ESMO 2024 ]
  • DESTINY-Gastric03: First-line T-DXd combinations with fluoropyrimidine and/or pembrolizumab demonstrated promising antitumour activity in metastatic HER2+ gastric cancer/gastroesophageal junction adenocarcinoma [Abstract 1401O. Janjigian Y, et al.]
    • KEYNOTE-811 and DESTINY-GASTRIC03 show that pembrolizumab added to trastuzumab and chemotherapy is a suitable treatment option for patients who are both HER2-positive and PD-L1 positive and not for patients who are PD-L1 negative
  • SHR-1701 in HER- patients: Trial showed that SHR-1701 (PD-L1/TGF-β bispecific) combined with CAPOX chemotherapy resulted in a significant OS benefit when used as first-line therapy for HER-2 negative gastric/gastroesophageal adenocarcinoma patients. China only study, so results not applicable outside China, also chemotherapy only control arm, so not clear what added benefit is over PD-1 alone [Peng Z, et al. Abstract LBA60, ESMO 2024]

 

  • Understand the latest highlights on upper GI cancer data from the ESMO 2024 conference and the implications for clinical practice  

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks

Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal programme. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI oesophagogastric task force, and is on the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and oesophageal cancer outreach and patient advocacy.

Assoc. Prof. Samuel J Klempner has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.

Prof. Chiara Cremolini and Prof. Hans Prenen share their views on practice-changing lower GI cancer data presented at the ESMO 2024 congress. 

  

Watch and listen as the experts reveal what they consider to be the key takeaways and the potential impacts on clinical practice.

 

Clinical takeaways

  • POD1UM-303/InterAACT 2: Addition of immunotherapy (retifanlimab) to chemotherapy (carboplatin and paclitaxel) improves PFS over current standard of care (SoC) in advanced squamous cell carcinoma of the anal canal and may become a new standard of care for these patients [Rao S, et al.Abstract LBA2, ESMO 2024]
  • RAMTAS/IKF643: The addition of the anti-angiogenic agent ramucirumab to trifluridine plus tipiracil did not result in an improvement in OS in heavily pre-treated chemotherapy-refractory mCRC patients. Subgroup analyses support potential improvements in OS in female patients and those with left sided tumours [Kasper-Virchow S, et al. Abstract LBA25, ESMO 2024]
  • FFCD 1703 POCHI: Investigated the effect of CAPOX plus bevacizumab plus pembrolizumab in first-line pMMR/MSS mCRC patients with a high tumour infiltrate of lymphocytes. Combination treatment resulted in a good response rate and an expected safety profile [Tougeron D, et al. Abstract 502O, ESMO 2024]
  • NICHE-2: Study showed a 3-year disease-free survival of 100% in patients with high-risk, locally advanced dMMR colon cancer with only 2 cycles of neoadjuvant immunotherapy (ipilimumab plus nivolumab)  [Chalabi M, et al. Abstract LBA24, ESMO 2024]
  • NICHE-3: Neoadjuvant treatment with nivolumab plus relatlimab led to a pathological response rate of 97% in patients with locally advanced dMMR colon cancer  [De Gooyer P, et al. Abstract 503O, ESMO 2024]
    • The results from NICHE-2 and NICHE-3 further support the use of neoadjuvant immunotherapy in dMMR colon cancer
  • IMHOTEP: A short course of neoadjuvant pembrolizumab as monotherapy in dMMR/MSI localised resectable CRC patients resulted in a 53% pathological complete response rate (pCR). The pCR rate increased with the number of cycles of pembrolizumab [De la Fouchardiere C, et al. Abstract 504O, ESMO 2024] 

  • Understand the latest highlights on lower GI cancer data from the ESMO 2024 conference and the implications for clinical practice  

Dr Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.

Hans Prenen obtained his medical degree and PhD at the Catholic University Leuven. He is currently the head of the Medical Oncology Department at the University Hospital Antwerp and director of the Oncology Clinical Trial Unit. He is member of several scientific organisations including the Belgian Society of Medical Oncology (board member since 2015) and the European Society of Medical oncology (scientific committee). He is a recognised international expert in the field of cancer and is regularly invited to national and international meetings and has published more than 200 peer reviewed scientific papers. He is principal investigator of several clinical trials with a focus on phase 1 and basket trials. His research interests relate to translational studies on targeted therapies, new anticancer therapies and understanding the molecular changes induced by anticancer therapy.

Prof. Sebastian Stintzing and Prof. Reinhard Dummer share their views on the latest data on BRAF-altered colorectal and other cancers (melanoma, brain, and solid tumours) presented at the ESMO 2024 congress.

 

Watch and listen as the experts reveal what they consider to be the key takeaways that could impact clinical practice. 

 

Clinical takeaways

  • BREAKWATER: Encorafenib plus cetuximab added to FOLFIRI was tolerable and showed promising efficacy (ORR, PFS and OS) during the safety lead-in phase of BREAKWATER for patients with BRAF V600E-mutated mCRC who had received ≤1 prior treatment for mCRC [Tabernero J, et al. Abstract 515MO, ESMO 2024]
  • CFT1946 in solid tumours: CFT1946, a novel, oral BRAF V600X degrader, was found to be well tolerated, demonstrated proof of mechanism with degradation observed in all post-treatment biopsies and showed anti-tumour activity in patients who had progressed on a BRAF inhibitor [Vieito M, et al. Abstract 612O, ESMO 2024]
  • Exarafenib and binimetinib in melanoma & solid tumours: Exarafenib, a next-generation pan-RAF inhibitor, when combined with binimetinib demonstrated a favourable AE profile and limited DLTs as well as encouraging anti-tumour activity in NRAS-mutant melanoma and BRAF-altered solid tumours [Cassier P, et al. Abstract 613MO, ESMO 2024]
  • ABM-1310 in brain tumours: ABM-1310, an innovative BRAF inhibitor with high brain blood-barrier penetration, was well tolerated and showed promising efficacy in patients with BRAF V600-mutated, recurrent primary brain tumours [Li W, et al. Abstract 453MO, ESMO 2024]
  • ImmunoCobiVem: Early switch to atezolizumab after run-in with vemurafenib plus cobimetinib led to an improvement in OS rates in patients with BRAF V600–positive melanoma but was not statistically significant. However, a relevant number of patients experienced rapid progression after early switch from targeted therapy to immune checkpoint inhibition [Schadendorf D, et al. Abstract LBA45, ESMO 2024]

 

This content is intended for HCPs outside the UK and ROI only.

  • Understand the latest highlights on BRAF-altered CRC and other cancers from the ESMO 2024 conference and the implications for clinical practice 

Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin. His research focuses on the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany. Prof. Stintzing is member of national and international cancer associations, member of the German S3 Guideline committee for colorectal cancer, and member of the steering committee of the working group Colorectal Carcinoma of the German AIO.

Prof. Sebastian Stintzing has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AMGEN, AstraZeneca, Bayer, BMS, CV6, Eisai, Isofol, Lilly, Merck KGaA, MSD, Pierre Fabre, Roche, Sanofi, Taiho, Takeda

Professor Reinhard Dummer is Deputy Director of the Dermatology Clinic at the University of Zurich.  He is a specialist in dermatology, dermatopathology, allergology and clinical immunology and his work focuses on the scientific investigation and treatment of skin cancers, in particular cutaneous melanoma and cutaneous T-cell lymphomas. Over the last few decades, he has become an international leader in the field of dermatology and this is reflected by frequent citations of his work in the literature.
 
Professor Dummer is Co-Director of Skintegrity.ch and a board member of the European Society of Dermatological Research (ESDR) and the European Association of Dermato-Oncology (EADO). He was President: Melanoma for ESMO and is currently a Faculty Member for the ESMO Faculty Group on Melanoma and Other Skin Tumours.  He has authored more than 1000 publications and been involved in more than 30 competitively funded research projects.

Prof. Reinhard Dummer has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bristol-Myers Squibb, Catalym, MaxiVAX SA, Merck, Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Second Genome, Sun Pharma, T3 Pharma, Takeda
Programme summary
  • clock Duration 6 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration 8 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Endorsement
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts
Brought to you by
DERMATOLOGY CONNECT

DERMATOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grant from Glenmark Pharmaceuticals, Bayer and Pierre Fabre Laboratories.

Meet the experts Independent IME approved

Lung cancer highlights from WCLC and ESMO 2024

Lung cancer highlights from WCLC and ESMO 2024

Dr Herbert H. Loong shares his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the WCLC and ESMO 2024 congresses.

 

Dr Loong reviews data and provides his key clinical takeaways from the studies below. 

 

 

Clinical takeaways

 

ROS1

  • TRUST-II: Taletrectinib demonstrated high and durable overall responses, robust IC activity in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC, and is a potential new therapy for this patient population. Data from TRUST-II supports the efficacy and safety of taletrectinib across regions and ethnicities [Liu G, et al. Abstract MA06.03, WCLC 2024]

KRAS

  • LOXO-RAS-20001: demonstrates the feasibility of combining KRAS G12C inhibitors with chemotherapy and immunotherapy. Preliminary efficacy was demonstrated with an ORR of 50% in a higher risk (PD-L1 low/negative) population. Olomorasib combined with chemo-immunotherapy demonstrated a manageable safety profile [Fujiwara Y, et al. Abstract OA14.04, WCLC 2024]

HER2 mutations

  • SOHO-01: Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant NSCLC. The safety profile of BAY 2927088 was manageable and consistent with previous reports [Le X, et al. Abstract PL04.03, WCLC 2024]
  • Beamion LUNG-1: Zongertinib demonstrated significant and clinically meaningful activity in patients with pre-treated NSCLC with a HER2 TKD mutation, including in those with brain metastases and was well tolerated [Ruiter G, et al. Abstract PL04.04, WCLC 2024]

HER2 Over expression

  • DESTINY-Lung03: T-DXd monotherapy demonstrated encouraging antitumor activity in patients with pretreated advanced or metastatic HER2-OE NSCLC, and had an acceptable safety profile, consistent with the known profile of T-DXd [Planchard D, et al. Abstract OA16.05, WCLC 2024]

ALK

  • ALKOVE-1: NVL-655 was well-tolerated and the emerging safety profile was consistent with ALK-selective, TRK-sparing design. Durable responses were observed in a heavily pre-treated population and across patient subgroups [Drilon A, et al. Abstract 1253O, ESMO 2024]

EGFR

  • MARIPOSA: Amivantamab plus lazertinib had significantly reduced the incidence of MET amplifications and EGFR resistance alterations versus osimertinib [Besse B, et al. Abstract LBA55, ESMO 2024]

 

Watch the short video update and download the accompanying slides to see the key data from these trials. 

  • Understand the clinical trial data and emerging profile of targeted therapies for the treatment of molecularly driven lung cancer 

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

 

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

 

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

 

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

 

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Dr Herbert H. Loong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda

Prof. David Planchard and Dr Federico Cappuzzo share their views on the latest data on BRAF-altered non-small cell lung cancer (NSCLC) presented at the ESMO 2024 congress.   

 

Watch and listen as the experts reveal what they consider to be the key takeaways that HCPs need to know.

 

Clinical takeaways

  • PHAROS: Long-term follow up of ~ 32 months from the PHAROS study showed that encorafenib plus binimetinib continued to show substantial antitumour activity in treatment-naïve BRAF-V600E mutant mNSCLC patients. The safety profile of the combination remained consistent with the earlier analysis [Riely G, et al. Abstract LBA56, ESMO 2024]
  • IFCT-1904 ENCO-BRAF: French study which showed antitumour activity in treatment-naïve BRAF V600E-mutant advanced NSCLC patients treated with encorafenib plus binimetinib. The safety profile was manageable and consistent with previous reports in NSCLC and melanoma [Planchard D, et al. Abstract 1259MO, ESMO 2024]
    • The results of the PHAROS and IFCT-1904 ENCO-BRAF trials confirm the validity of targeting BRAF and MEK in BRAF V600E-mutant non-small cell lung cancer
  • 1L IO vs BRAF and MEK inhibitors: A retrospective study which looked at clinicopathologic and outcomes data from patients with mNSCLC who received first-line treatment with either an ICI ±CT or a BRAFi + MEKi. Outcomes varied by line of treatment, smoking pack years and PD-L1 status, suggesting clinical factors should be used to tailor first-line therapy in these patients [Di Federico A, et al. Abstract 1299P, ESMO 2024]
  • MoST: First line treatment with vemurafenib plus cobimetinib resulted in significant clinical antitumour activity in treatment naïve BRAF V600E-mutated NSCLC [Lin F, et al. Abstract 623P, ESMO 2024]

 

Watch the short video update to hear more about the key data from BRAF-altered lung cancer trials. 

 

This content is intended for HCPs outside the UK and ROI only.

  • Understand the latest highlights on BRAF-altered NSCLC data from the ESMO 2024 conference  

Dr. Federico Cappuzzo is the Director of Medical Oncology at the National Cancer Institute Regina Elena in Rome.

In November 1992, he graduated with highest honours in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree with highest honours in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997.

From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA).

For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting professor in Medical Oncology at University of Colorado in Denver (USA).

From January 2010 to April 2016 he was the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno. From April 2016 to September 2020 he was Director of Oncology and Hematology Department at AUSL Romagna in Ravenna.

Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European

Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and

International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Memberof the editorial board of Lung Cancer. From 2013 to 2017 he was the Chairman of the Educational Committee of IASLC. He is the author of more than 250 papers in peer-review journals, mainly in translational research in lung cancer.

Dr Federico Cappuzzo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, ILLUMINA, Lilly, OSE, Mirati, MSD, Novocure, Pharmamar, Pfizer, Roche, Thermofisher, Sanofi, Takeda
Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Pierre Fabre Laboratories.

Meet the experts Independent IME approved
Programme summary
  • clock Duration 8 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Endorsement
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Pierre Fabre Laboratories.

Meet the experts Independent IME approved

HCC highlights from ESMO 2024

Dr Richard Finn shares his views on the latest HCC data on immunotherapy (IO) and IO-based treatments presented at the ESMO 2024 congress.  

 

Dr Finn reviews data and provides clinical takeaways from the studies below.

 

Clinical takeaways

 

  • HIMALAYA: Results from the extended follow-up set a new benchmark in unresectable HCC, with one in five patients alive with single tremelimumab regular interval durvalumab (STRIDE) at 5 years [Rimassa L, et al. Abstract 947MO, ESMO2024]
  • CheckMate 9DW: Further supports nivolumab + ipilimumab as a potential first-line treatment option for patients with unresectable HCC [Decaens T, et al. Abstract 965MO, ESMO 2024]
  • LEAP-012: Met its primary endpoint. Lenvatinib + pembrolizumab + TACE showed a statistically significant and clinically meaningful improvement in PFS and an early trend towards improvement in OS versus placebo + TACE in patients with intermediate HCC [Llovet J, et al. Abstract LBA3, ESMO 2024]
  • IMbrave050: Does not support atezolizumab + bevacizumab as an adjuvant therapy for all high-risk HCC [Yopp A, et al. Abstract LBA39, ESMO 2024]

 

Watch the short video update and download the accompanying slides to see the key data from these trials.

 

AstraZeneca has provided a sponsorship grant towards this independent Programme.

Understand the latest practice changing HCC data on IO and IO-based treatments from the conference and how this could be implemented in clinical practice.

Dr Richard Finn is a professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr Dennis Slamon. He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology. He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. His research interests are focused in the development of targeted therapeutics for solid tumors across histologies to support the larger efforts of the department. His personal interests lie in the development of these targeted agents in Hepato-biliary and breast cancers. He has two-half days dedicated to patient care, one of which is as a leader in the multi-disciplinary hepato-biliary cancer program at UCLA where he is involved with clinical studies aimed at bringing novel therapeutics into the treatment of patients with these malignancies.

Programme summary
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca. 
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca. 
Endorsement
Global Liver Institute Blue Faery DiCE
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Breast cancer highlights from ESMO 2024

Prof. François-Clément Bidard shares his views on the latest breast cancer data presented at the ESMO 2024 congress.   

 

Watch as he reveals what he considers to be the key clinical takeaways from the following trials: 

  • Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study [Schmid P, et al. Abstract LBA4, ESMO 2024]
  • Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINYBreast-12 primary results [Lin N, et al. Abstract LBA18, ESMO 2024]
  • Adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer: 4-year outcomes from the NATALEE Trial [Fasching P, et al. Abstract LBA13, ESMO 2024]

Understand the latest highlights on practice-changing breast cancer data from the ESMO 2024 conference 

François-Clément Bidard, MD PhD, is a Professor of Medical Oncology in Paris and Saint-Cloud, France. His clinical work is dedicated to breast cancer care, whereas his translational and clinical research focuses on all forms of liquid biopsy and new therapies to move ahead of cancer resistance.

Prof. François-Clément Bidard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Bidart discloses financial support/sponsorship from AstraZeneca, Daiichi-Sankyo, Caris, Exact Sciences, General Electrics Healthcare, GSK, Inatherys, Lilly, Merck KGaA, Menarini Silicon Biosystems, Menarini/Stemline, Novartis, Pfizer, Prolynx, Rain Oncology, Roche, SAGA Diagnostics, Seagen, Sanofi
Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from COR2ED.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from COR2ED.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

GU cancer highlights from ESMO 2024

In this short video update, Dr. Ray Manneh Kopp shares his perspective on the latest data presented at the ESMO 2024 congress, covering renal, bladder and prostate cancers.   

 

Watch the video for his summary of the key clinical takeaways from the following trials: 

  • A randomised multicenter open label phase 3 trial comparing enzalutamide vs a combination of Radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC: First results of EORTC-GUCG 1333/PEACE-3 [Gillessen S, et al. Abstract LBA1, ESMO 2024]
  • A randomised phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) [Powles T, et al. Abstract LBA5, ESMO 2024]
  • Tivozanib–nivolumab vs tivozanib monotherapy in patients with RCC following 1 or 2 prior therapies including an immune checkpoint inhibitor – Results of the phase 3 TiNivo-2 Study [Choueiri T, et al. Abstract LBA73, ESMO 2024]

  • Understand the latest highlights on practice-changing GU cancer data from the ESMO 2024 conference  

Scientific director at Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Chief of Genitourinary Unit and Clinical Research Unit. Medical Oncologist at Clínica Portoazul, Barranquilla, Colombia. I completed medical school at Universidad del Norte, Barranquilla Colombia.  Medical oncologist from University Hospital 12 de Octubre in Madrid, Genitourinary Fellow in the GU unit at  University Hospital 12 de Octubre. Master in molecular oncology from Centro de estudios biosanitarios, CNIIO, ESO. Founder of Grupo de Oncología Genitourinaria de Colombia.  Member of SEOM, ACHO and LACOG-GU. I focus my practice on patients with prostate, bladder, kidney and testicular cancer. 

Dr Ray Manneh Kopp has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Dr Reddys, Roche, Janssen, Lilly, MSD, Novartis and Technofarma.
Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from COR2ED.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from COR2ED.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Precision oncology poster presentation

Precision oncology poster presentation

We are pleased to share that PRECISION ONCOLOGY CONNECT presented the results from a non-small cell lung cancer global patient and caregiver survey in a poster at ESMO 2024.

 

Read more about the survey and download the poster: Assessing biomarker testing awareness among patients and caregivers in NSCLC

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025
PRECISION ONCOLOGY CONNECT BREAST CANCER CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca
Explore all programmes